grant
Nef in impaired efferocytosis: a novel mechanism for vascular disease in HIV
Organization BRIGHAM AND WOMEN'S HOSPITALLocation BOSTON, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AIDSAIDS VirusASCVDATAC sequencingATAC-seqATACseqAccelerationAcquired Immune DeficiencyAcquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome VirusAddressAgingApoptoticAreaArterial Fatty StreakAssayAssay for Transposase-Accessible Chromatin using sequencingAtherogenicityAtheromaAtheromatousAtheromatous degenerationAtheromatous plaqueAtherosclerosisAtherosclerotic Cardiovascular DiseaseAtherosclerotic capAttenuatedBioassayBiologicalBiological AssayBiologyBlood VesselsCell BodyCellsChronicClinicalDataData ScienceDevelopmentDiseaseDisorderDrugsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEquilibriumEventFamilyFeedbackFibrous CapFutureGeneral PopulationGeneral PublicGoalsHIVHIV InfectionsHIV Long-Term SurvivorsHIV-1 Long-Term SurvivorsHTLV-III InfectionsHTLV-III-LAV InfectionsHeterogeneityHumanHuman Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsImmuneImmunesImpairmentIn VitroInflammationInflammatoryInflammatory ResponseInterdisciplinary ResearchInterdisciplinary StudyKI miceKinasesKnock-in MouseLAV-HTLV-IIILeannessLesionLymphadenopathy-Associated VirusMacrophageMacrophage ActivationMediatorMedicationMiceMice MammalsModern ManModernizationMolecularMultidisciplinary CollaborationMultidisciplinary ResearchMultiomic DataMurineMusMφNecrosisNecroticNetwork AnalysisPathway AnalysisPathway interactionsPatientsPersonsPhagocytosisPharmaceutical PreparationsPhenotypePhosphotransferase GenePhosphotransferasesPlayPost-Transcriptional Gene SilencingProteinsProteomicsRNA InterferenceRNA SilencingRNAiReceptor ProteinResolutionRoleSequence-Specific Posttranscriptional Gene SilencingSurvivorsSystemTestingThinnessTransphosphorylasesVascular DiseasesVascular DisorderViral BurdenViral LoadViral Load resultViral load measurementVirionVirus ParticleVirus-HIVantiretroviral therapyantiretroviral treatmentassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingatherogenesisatheromatosisatheroprotectionatheroprotectiveatherosclerosis plaqueatherosclerosis riskatherosclerotic diseaseatherosclerotic lesionsatherosclerotic plaqueatherosclerotic riskatherosclerotic vascular diseaseattenuateattenuatesbalancebalance functionbasebasesbiologicblood vessel disordercardiovascular riskcardiovascular risk factorclinical translationclinically translatabledata integrationdevelopmentaldrug/agentepigeneticallyexperimentexperimental researchexperimental studyexperimentsextracellular vesiclesglobal healthhigh riskin vivoknockin micelatent HIV reservoirlatent HIV-1 reservoirlatent HIV1 reservoirlipid based nanoparticlelipid nanoparticlemultiomicsmultiple omic datamultiple omicsnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypanomicspathwayplaque capplaques in atherosclerosisprecision medicineprecision-based medicinereceptorresolutionsscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell analysissingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial roletherapeutic targettranscriptomicsvascularvascular dysfunctionvascular inflammationvasculopathyvirus load
Description preview
Project Summary
Anti-retroviral therapy (ART) has protected many HIV patients against the development of AIDS. HIV
infection has become a treatable disease. Increased risk for atherosclerotic vascular diseases in long-term
HIV survivors or people living with HIV (PLWH) with no detectable virus load, however, is projected to
become a global health…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click